ImmunityBio's stock is moving higher after the FDA announced it would review a possible label expansion for the company's core Anktiva drug.

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, invites current and prospective investors to its Investor Day program to be held on Tuesday, ...

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced that it intends to offer and sell, subject to market and other conditions, ...

ImmunityBio’s findings showed that ANKTIVA plus BCG generated savings of up to $151,438 per cystectomy avoided over a three-year period in a U.S. Medicare population. ・The analysis also found lower ...

ImmunityBio Inc. IBRX presented two indirect treatment comparison analyses, highlighting efficacy and safety outcomes for ...

ImmunityBio, Inc. receives a Strong Buy rating, driven by ANKTIVA's compelling clinical data and major regulatory catalysts ...

Stock Moves Higher Following Patent AnnouncementShares of ImmunityBio (NASDAQ:IBRX) gained 4. 5% in premarket trading on ...

UK-based study identifies key patient-centered factors influencing treatment preferences in high-risk NMIBCCULVER CITY, Calif ...

ImmunityBio, Inc. (NASDAQ: IBRX), a vertically integrated commercial-stage immunotherapy company, today announced results ...

ImmunityBio (IBRX) stock jumps as the FDA agrees to review the company's bid to expand the label for bladder cancer therapy ...

View ImmunityBio Inc IBRX stock quote prices, financial information, real-time forecasts, and company news from CNN.

Lawyers at Kahn Swick & Foti, LLC are available to discuss your legal options. About the Lawsuit ImmunityBio and certain of its executives are charged with failing to disclose material information ...